Stock Scorecard
Stock Summary for Qiagen NV (QGEN) - $41.08 as of 4/26/2024 3:40:49 PM EST
Total Score
11 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for QGEN
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for QGEN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for QGEN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for QGEN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for QGEN
Financial Details for QGEN
Company Overview |
|
---|---|
Ticker | QGEN |
Company Name | Qiagen NV |
Country | USA |
Description | QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 4/30/2024 |
Stock Price History |
|
Last Day Price | 41.08 |
Last Day Price Updated | 4/26/2024 3:40:49 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 886,594 |
52-Week High | 47.74 |
52-Week Low | 34.77 |
Last Price to 52 Week Low | 18.15% |
Valuation Measures |
|
Trailing PE | 27.40 |
Industry PE | 64.46 |
Sector PE | 56.64 |
5-Year Average PE | 17.53 |
Free Cash Flow Ratio | 13.60 |
Industry Free Cash Flow Ratio | 20.47 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 1.99 |
Total Cash Per Share | 3.02 |
Book Value Per Share Most Recent Quarter | 17.20 |
Price to Book Ratio | 2.34 |
Industry Price to Book Ratio | 7.85 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 4.53 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 221,357,000 |
Market Capitalization | 9,093,345,560 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | 1/30/2024 |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 1.28 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 1.28 |
Trailing Annual Dividend Yield | 3.07% |
Forward Annual Dividend Rate | 1.28 |
Forward Annual Dividend Yield | 3.07% |
5-Year Dividend Payments Count | 1 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | 84.21% |
Income Statement |
|
Quarterly Earnings Growth YOY | 8.90% |
Annual Earnings Growth | -19.35% |
Reported EPS 12 Trailing Months | 1.52 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 2.07 |
Net Income Twelve Trailing Months | 341,303,000 |
Net Income Past Year | 341,303,000 |
Net Income Prior Year | 423,211,000 |
Quarterly Revenue Growth YOY | 2.20% |
5-Year Revenue Growth | 5.53% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 668,084,000 |
Total Cash Past Year | 668,084,000 |
Total Cash Prior Year | 730,669,000 |
Net Cash Position Most Recent Quarter | -253,740,000 |
Net Cash Position Past Year | -253,740,000 |
Long Term Debt Past Year | 921,824,000 |
Long Term Debt Prior Year | 1,471,898,000 |
Total Debt Most Recent Quarter | 921,824,000 |
Equity to Debt Ratio Past Year | 0.81 |
Equity to Debt Ratio Most Recent Quarter | 0.81 |
Total Stockholder Equity Past Year | 3,807,764,000 |
Total Stockholder Equity Prior Year | 3,466,611,000 |
Total Stockholder Equity Most Recent Quarter | 3,807,764,000 |
Options |
|
Put/Call Ratio | 0.06 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.59 |
MACD Signal | -0.74 |
20-Day Bollinger Lower Band | 40.28 |
20-Day Bollinger Middle Band | 43.18 |
20-Day Bollinger Upper Band | 46.08 |
Beta | 0.42 |
RSI | 44.92 |
50-Day SMA | 42.95 |
200-Day SMA | 47.62 |
System |
|
Modified | 4/27/2024 9:47:36 AM EST |